Canvas Wealth Advisors LLC Has $350,000 Holdings in Hologic, Inc. $HOLX

Canvas Wealth Advisors LLC lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 67.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,334 shares of the medical equipment provider’s stock after selling 10,824 shares during the quarter. Canvas Wealth Advisors LLC’s holdings in Hologic were worth $350,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Chung Wu Investment Group LLC acquired a new stake in shares of Hologic during the 2nd quarter worth about $26,000. Zions Bancorporation National Association UT acquired a new stake in shares of Hologic during the 1st quarter worth about $34,000. Cromwell Holdings LLC increased its position in shares of Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares in the last quarter. Allworth Financial LP increased its position in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Hologic during the 1st quarter worth about $42,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.88% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Morgan Stanley increased their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Finally, Mizuho set a $75.00 price objective on shares of Hologic in a report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $80.15.

Hologic Stock Up 2.0%

Shares of NASDAQ HOLX opened at $69.85 on Monday. The firm has a market capitalization of $15.54 billion, a PE ratio of 28.98, a price-to-earnings-growth ratio of 2.40 and a beta of 0.63. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The firm’s 50-day moving average is $67.11 and its 200-day moving average is $63.54.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.